Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:BHC NASDAQ:HCM NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$18.59-11.6%$20.50$89.95▼$99.05$538.83M0.9553,591 shs2.69 million shsBHCBausch Health Cos$5.03-5.4%$5.46$4.43▼$8.69$1.98B0.41.48 million shs3.96 million shsHCMHUTCHMED$11.52+1.1%$13.71$11.10▼$19.50$1.99B0.2640,064 shs139,099 shsRXRXRecursion Pharmaceuticals$3.61-4.7%$3.28$2.77▼$7.18$2.01B1.0417.44 million shs20.73 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-11.64%-16.30%-23.28%+33.64%+156.41%BHCBausch Health Cos-5.46%-6.77%-11.09%-10.90%+12.04%HCMHUTCHMED+1.05%-1.96%-13.38%-15.60%-15.29%RXRXRecursion Pharmaceuticals-4.75%+21.96%+6.49%-0.82%-17.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$18.59-11.6%$20.50$89.95▼$99.05$538.83M0.9553,591 shs2.69 million shsBHCBausch Health Cos$5.03-5.4%$5.46$4.43▼$8.69$1.98B0.41.48 million shs3.96 million shsHCMHUTCHMED$11.52+1.1%$13.71$11.10▼$19.50$1.99B0.2640,064 shs139,099 shsRXRXRecursion Pharmaceuticals$3.61-4.7%$3.28$2.77▼$7.18$2.01B1.0417.44 million shs20.73 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics-11.64%-16.30%-23.28%+33.64%+156.41%BHCBausch Health Cos-5.46%-6.77%-11.09%-10.90%+12.04%HCMHUTCHMED+1.05%-1.96%-13.38%-15.60%-15.29%RXRXRecursion Pharmaceuticals-4.75%+21.96%+6.49%-0.82%-17.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ABHCBausch Health Cos 1.80Reduce$8.0059.20% UpsideHCMHUTCHMED 2.40Hold$16.8045.83% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10124.38% UpsideCurrent Analyst Ratings BreakdownLatest AVTE, RXRX, HCM, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/1/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/10/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $20.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ABHCBausch Health Cos$10.27B0.18$6.88 per share0.73$1.02 per share4.93HCMHUTCHMED$548.51M3.66$2.72 per share4.23$7.17 per share1.61RXRXRecursion Pharmaceuticals$74.68M25.62N/AN/A$2.14 per share1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ABHCBausch Health Cos$157M-$3.24N/A1.33N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)HCMHUTCHMED$456.91MN/AN/A19.86N/AN/AN/AN/A8/3/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest AVTE, RXRX, HCM, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion3/6/2026H2 2025HCMHUTCHMED$2.50$0.0060-$2.4940N/A$290.50 million$135.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78BHCBausch Health Cos54.681.320.97HCMHUTCHMED0.054.964.83RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ABHCBausch Health Cos78.65%HCMHUTCHMED8.82%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%BHCBausch Health Cos20.67%HCMHUTCHMED3.60%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableBHCBausch Health Cos20,300373.81 million296.55 millionOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableAVTE, RXRX, HCM, and BHC HeadlinesRecent News About These CompaniesThree AI Healthcare Stocks Chart Distinct Growth Trajectories3 hours ago | nai500.comNRecursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?June 2 at 6:34 PM | fool.comRecursion to Participate in Upcoming Investor ConferencesJune 2 at 8:32 AM | finance.yahoo.comRecursion to Participate in Upcoming Investor ConferencesJune 2 at 8:00 AM | globenewswire.comLingotto Investment Management LLP Buys 1,255,980 Shares of Recursion Pharmaceuticals, Inc. $RXRXJune 2 at 6:55 AM | marketbeat.comRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesMay 29, 2026 | finance.yahoo.comRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesMay 29, 2026 | globenewswire.comVerge, following trial failure, rebrands its AI drug discovery ambitionsMay 27, 2026 | biopharmadive.comBRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.9% Higher - Here's WhyMay 27, 2026 | marketbeat.comRecursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)May 27, 2026 | marketbeat.comRecursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?May 25, 2026 | fool.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24, 2026 | finance.yahoo.comA Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth ProspectsMay 23, 2026 | finance.yahoo.comMorgan Stanley Raises its Price Target on Recursion (RXRX)May 22, 2026 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - Here's What HappenedMay 19, 2026 | marketbeat.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | finance.yahoo.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | globenewswire.comQ4 Earnings Estimate for RXRX Issued By KeyCorpMay 18, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by BrokeragesMay 16, 2026 | marketbeat.comRecursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowMay 14, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVTE, RXRX, HCM, and BHC Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$18.59 -2.45 (-11.64%) As of 06/1/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Bausch Health Cos NYSE:BHC$5.03 -0.29 (-5.37%) Closing price 06/2/2026 03:59 PM EasternExtended Trading$5.02 0.00 (-0.06%) As of 06/2/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.HUTCHMED NASDAQ:HCM$11.52 +0.12 (+1.05%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$11.52 0.00 (0.00%) As of 06/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Recursion Pharmaceuticals NASDAQ:RXRX$3.61 -0.18 (-4.75%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$3.60 0.00 (-0.14%) As of 06/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
